Efficacy, safety and feasibility of treatment of chronic HCV infection with directly acting agents in hematopoietic stem cell transplant recipients - Study of infectious diseases working party of EBMT
Copyright © 2021 The British Infection Association. Published by Elsevier Ltd. All rights reserved..
OBJECTIVES: Limited data is available on HCV directly acting agents (DAAs) in haematopoietic stem cell transplant (HSCT) recipients. This study aimed at reporting the characteristics, treatment practices and treatment efficacy in HSCT recipients with chronic HCV.
METHODS: Prospective observational study from EBMT Infectious Diseases Working Party (IDWP). Patients with chronic HCV infection were included.
RESULTS: Between 12/2015 and 07/2018, 45 patients were included: male in 53%; median age 49 years (range, 8-75); acute leukaemia in 48.9%, lymphoma in 17.7%, non-malignant disorders in 22.3%; allogeneic HSCT in 84%; 77.8% no immunosuppressive treatment. Genotypes 1, 2, 3 and 4 were detected in 54.5%, 20.5%, 13.6% and 11.4%, respectively; advanced fibrosis in 40%, including cirrhosis in 11.4%. Overall, 37 (82.2%) patients received DAAs, at a median of 8.4 years after HSCT (16.2% within 6 months from HSCT). Sofosbuvir-based treatment was given to 62.2%. Thirty-five patients completed planned treatment course, with sustained virological response (SVR) of 89.1%, and 94.3% (33/35) in those who completed the treatment. Side effects possibly related to DAAs were reported in 5 (14%) and did not require treatment discontinuation.
CONCLUSIONS: DAAs treatment was effective, safe and feasible in this cohort of mainly allogeneic HSCT recipients with mild/moderate liver damage.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:84 |
|---|---|
| Enthalten in: |
The Journal of infection - 84(2022), 1 vom: 15. Jan., Seite 71-79 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mikulska, Malgorzata [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 26.01.2022 Date Revised 26.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jinf.2021.10.024 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332950778 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332950778 | ||
| 003 | DE-627 | ||
| 005 | 20231225220630.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jinf.2021.10.024 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1109.xml |
| 035 | |a (DE-627)NLM332950778 | ||
| 035 | |a (NLM)34757138 | ||
| 035 | |a (PII)S0163-4453(21)00539-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mikulska, Malgorzata |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy, safety and feasibility of treatment of chronic HCV infection with directly acting agents in hematopoietic stem cell transplant recipients - Study of infectious diseases working party of EBMT |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.01.2022 | ||
| 500 | |a Date Revised 26.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The British Infection Association. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a OBJECTIVES: Limited data is available on HCV directly acting agents (DAAs) in haematopoietic stem cell transplant (HSCT) recipients. This study aimed at reporting the characteristics, treatment practices and treatment efficacy in HSCT recipients with chronic HCV | ||
| 520 | |a METHODS: Prospective observational study from EBMT Infectious Diseases Working Party (IDWP). Patients with chronic HCV infection were included | ||
| 520 | |a RESULTS: Between 12/2015 and 07/2018, 45 patients were included: male in 53%; median age 49 years (range, 8-75); acute leukaemia in 48.9%, lymphoma in 17.7%, non-malignant disorders in 22.3%; allogeneic HSCT in 84%; 77.8% no immunosuppressive treatment. Genotypes 1, 2, 3 and 4 were detected in 54.5%, 20.5%, 13.6% and 11.4%, respectively; advanced fibrosis in 40%, including cirrhosis in 11.4%. Overall, 37 (82.2%) patients received DAAs, at a median of 8.4 years after HSCT (16.2% within 6 months from HSCT). Sofosbuvir-based treatment was given to 62.2%. Thirty-five patients completed planned treatment course, with sustained virological response (SVR) of 89.1%, and 94.3% (33/35) in those who completed the treatment. Side effects possibly related to DAAs were reported in 5 (14%) and did not require treatment discontinuation | ||
| 520 | |a CONCLUSIONS: DAAs treatment was effective, safe and feasible in this cohort of mainly allogeneic HSCT recipients with mild/moderate liver damage | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a DAAs | |
| 650 | 4 | |a HCV | |
| 650 | 4 | |a HSCT | |
| 650 | 4 | |a Transplant | |
| 650 | 4 | |a Treatment | |
| 650 | 4 | |a sofosbuvir | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Knelange, Nina |e verfasserin |4 aut | |
| 700 | 1 | |a Nicolini, Laura Ambra |e verfasserin |4 aut | |
| 700 | 1 | |a Tridello, Gloria |e verfasserin |4 aut | |
| 700 | 1 | |a Santarone, Stella |e verfasserin |4 aut | |
| 700 | 1 | |a Di Bartolomeo, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a de la Camara, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Cuéllar, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Velardi, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Perruccio, Katia |e verfasserin |4 aut | |
| 700 | 1 | |a Ljungman, Per |e verfasserin |4 aut | |
| 700 | 1 | |a Zaucha, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Piekarska, Agnieszka |e verfasserin |4 aut | |
| 700 | 1 | |a Basak, Grzegorz |e verfasserin |4 aut | |
| 700 | 1 | |a Karakulska-Prystupiuk, Ewa |e verfasserin |4 aut | |
| 700 | 1 | |a Angelucci, Emanuele |e verfasserin |4 aut | |
| 700 | 1 | |a Ciceri, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Lupo-Stanghellini, Maria Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Fouillard, Loic |e verfasserin |4 aut | |
| 700 | 1 | |a García-Cadenas, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Menconi, Mariacristina |e verfasserin |4 aut | |
| 700 | 1 | |a Blau, Igor Wolfgang |e verfasserin |4 aut | |
| 700 | 1 | |a Nassi, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Cesaro, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Styczynski, Jan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infection |d 1982 |g 84(2022), 1 vom: 15. Jan., Seite 71-79 |w (DE-627)NLM012791822 |x 1532-2742 |7 nnns |
| 773 | 1 | 8 | |g volume:84 |g year:2022 |g number:1 |g day:15 |g month:01 |g pages:71-79 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jinf.2021.10.024 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 84 |j 2022 |e 1 |b 15 |c 01 |h 71-79 | ||